Gan & Lee Pharmaceuticals reported on June 30, 2026 in Annals of Internal Medicine that its investigational GLP-1 receptor agonist bofanglutide, dosed once every two weeks, lowered HbA1c at least as much as weekly semaglutide in a 272-patient phase 2b trial in adults with type 2 diabetes. The headline is the dosing interval: half the injections, comparable-or-better glucose control.
Bofanglutide joins a growing field of long-acting agonists chasing the same goal — matching the efficacy of weekly semaglutide and tirzepatide while cutting how often patients have to inject. This one is not available to buy anywhere; it matters as a signal about where the category is heading, not as a product decision for today.
Research-context information only. Compounds discussed below are research peptides and supplements; some are investigational drugs not approved by the FDA. Protocols, doses, and reactions reported come from published research and self-reported community sources. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the Phase 2b Trial Showed
The trial randomized 272 Chinese adults with type 2 diabetes across 37 sites. Participants had a mean age of 50.8 years, were 61% male, carried a mean baseline BMI of 27.9, and started with a mean HbA1c of 8.35%. The primary endpoint was change in HbA1c from baseline to week 24.
Patients were assigned to one of five arms: bofanglutide titrated to 12, 18, or 24 mg every two weeks; bofanglutide 24 mg once weekly; or semaglutide 1 mg once weekly as the active comparator — the highest semaglutide dose approved for type 2 diabetes.
The HbA1c reductions at 24 weeks:
| Arm | HbA1c change from baseline |
|---|---|
| Bofanglutide 12 mg biweekly | −1.87% |
| Bofanglutide 18 mg biweekly | −2.28% |
| Bofanglutide 24 mg biweekly | −1.94% |
| Bofanglutide 24 mg weekly | −2.32% |
| Semaglutide 1 mg weekly | −1.60% |
Treatment differences versus semaglutide ranged from −0.27 to −0.72 percentage points, with the largest gaps from the 18 mg biweekly and 24 mg weekly arms. Between 63% and 75% of bofanglutide patients reached an HbA1c below 7.0%, compared with 70% on semaglutide. Fasting glucose, body weight, BMI, and waist circumference all improved across the treatment groups.
The investigators summarized it plainly: the reductions "seemed at least as large or larger when compared with 1 mg of semaglutide QW, the highest approved dose for T2DM."
The catch is tolerability. Overall adverse events ran 97.7% with bofanglutide versus 94.4% with semaglutide, and gastrointestinal events — nausea, vomiting, diarrhea — occurred in 81.8% to 87.3% of bofanglutide recipients versus 51.9% on semaglutide, concentrated during dose escalation. Discontinuations for adverse events spanned 7.5% to 18.5% across bofanglutide arms against 14.8% for semaglutide. Most events were graded mild to moderate, but the GI burden of the biweekly loading is real.
A separate Gan & Lee phase 2b trial in Chinese adults with overweight or obesity, published in Signal Transduction and Targeted Therapy, is testing bofanglutide specifically for weight loss — the obesity companion to this diabetes readout.
What This Means for GLP-1 Buyers
Practically, nothing changes about what you can buy today. Bofanglutide is an investigational molecule owned by Gan & Lee, studied so far only in China, and available exclusively inside clinical trials. It will not appear in research-peptide vendor catalogs or 503A compounding pharmacies for years — likely 2028 at the earliest even if global phase 3 trials start soon. There is no grey-market shortcut to an unapproved, patent-protected asset that hasn't cleared phase 2 in Western populations.
What the readout confirms is the direction of the whole category: less-frequent dosing is the next competitive battleground, and efficacy is no longer the only axis that matters. Weekly semaglutide and tirzepatide already won the induction fight. The open question is convenience — how few injections it takes to get and keep the result.
For anyone weighing GLP-1 options right now, the decision still comes down to the three weekly compounds that are actually available:
- Semaglutide remains the most-studied, lowest-cost entry point. Bofanglutide's benchmark in this trial was semaglutide 1 mg — a reminder that semaglutide sets the bar the whole field measures against. Compare current pricing at best semaglutide vendors.
- Tirzepatide (dual GIP/GLP-1) delivers more weight loss than semaglutide in head-to-head data and is the step up for buyers prioritizing magnitude. See best tirzepatide vendors.
- Retatrutide (triple GIP/GLP-1/glucagon) is the current efficacy ceiling, with phase 3 weight loss near 28-30%. Buyers chasing maximum results go here — best retatrutide vendors.
Vendor pricing on all three moves week to week, and stacked discount codes across the recommended vendor list run another 20-50% off list. Track live coupons at /deals.
